Xiuqian Mu, MD, PhD, professor of ophthalmology at the Jacobs School of Medicine and Biomedical Sciences, has received additional funding from the National Eye Institute for his research on retinal ...
Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. These changes are ...
Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal ...
National Eye Institute (NEI) scientists have found that the way the retina metabolizes glucose directly controls which genes get switched on and off in light-sensing photoreceptors. The findings ...
These vascularized vROs exhibit improved function of optic nerve cells and, for the first time, form fully functional light-signaling pathways from the photoreceptors to the retinal ganglion cells.
Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...
Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with ...
Edward Kang’s RetinaMind analyzes patients’ retinal images and accurately diagnoses neurodevelopmental disorders 89 percent ...
Optain Health, a startup that built artificial-intelligence-powered retinal screening technology, acquired EyePACS to add its teleophthalmology network and expand access to eye disease screening in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results